{"id":"tegafur-uracil","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression (leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Gastrointestinal toxicity (nausea, diarrhea, stomatitis)"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL235993","moleculeType":"Small molecule","molecularWeight":"200.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tegafur is a prodrug of 5-fluorouracil (5-FU) that undergoes hepatic metabolism to release active 5-FU. Uracil is a competitive inhibitor of dihydrouracil dehydrogenase, which normally degrades 5-FU, thereby prolonging 5-FU exposure and enhancing its cytotoxic effects. The combination allows for oral administration with improved bioavailability compared to intravenous 5-FU.","oneSentence":"Tegafur-uracil is a combination prodrug that is converted to fluorouracil in the body to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:28.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Gastric cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT00905047","phase":"PHASE3","title":"Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-11-14","conditions":"Colorectal Cancer","enrollment":89},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT06461910","phase":"PHASE2","title":"Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zekuan Xu","startDate":"2024-06-14","conditions":"Gastric Cancer, Esophagogastric Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":"Advanced Biliary Tract Carcinoma","enrollment":30},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":"Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":102},{"nctId":"NCT06739252","phase":"PHASE2","title":"Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA","status":"TERMINATED","sponsor":"Peking University","startDate":"2024-12-31","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma","enrollment":1},{"nctId":"NCT07372300","phase":"PHASE3","title":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shih-Kai Hung","startDate":"2025-09-23","conditions":"Locally Advanced Rectal Carcinoma","enrollment":126},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07178340","phase":"PHASE2","title":"Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-18","conditions":"Hepatoid Adenocarcinoma of Stomach","enrollment":30},{"nctId":"NCT05934331","phase":"PHASE2","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","status":"RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2023-07-27","conditions":"Malignant Neoplasms of Digestive Organs","enrollment":276},{"nctId":"NCT07165847","phase":"PHASE2","title":"Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-07-23","conditions":"Immunotherapy, Gastric Cancer (GC), Radiotherapy","enrollment":40},{"nctId":"NCT07161453","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-09-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":500},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT02363400","phase":"PHASE3","title":"A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12-14","conditions":"Nasopharyngeal Carcinoma","enrollment":10},{"nctId":"NCT01720563","phase":"PHASE2","title":"A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy","status":"TERMINATED","sponsor":"PhytoHealth Corporation","startDate":"2012-12","conditions":"Cancer-related Fatigue","enrollment":17},{"nctId":"NCT06988956","phase":"PHASE2","title":"Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-03-31","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":95},{"nctId":"NCT03406299","phase":"PHASE2","title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-19","conditions":"Biliary Tract Neoplasms","enrollment":92},{"nctId":"NCT04415853","phase":"PHASE3","title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-01-21","conditions":"Esophageal Cancer","enrollment":416},{"nctId":"NCT05223088","phase":"PHASE2","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-10-31","conditions":"Immunotherapy, Gastrict Cancer","enrollment":40},{"nctId":"NCT06427005","phase":"PHASE2","title":"Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC","status":"RECRUITING","sponsor":"Meng Qiu","startDate":"2023-02-20","conditions":"Fruquintinib, S-1, Raltitrexed","enrollment":66},{"nctId":"NCT04260269","phase":"","title":"Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study","status":"ENROLLING_BY_INVITATION","sponsor":"Helsinki University Central Hospital","startDate":"2018-06-01","conditions":"Solid Tumor","enrollment":200},{"nctId":"NCT06662877","phase":"PHASE2, PHASE3","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-25","conditions":"Biliary Tract Cancer, Second Line Treatment, Chemotherapy","enrollment":206},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","enrollment":361},{"nctId":"NCT06603974","phase":"NA","title":"The Efficacy and Safety of Benmelstobart for GC/EGC","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-10-16","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT03175679","phase":"PHASE1","title":"Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC","status":"COMPLETED","sponsor":"Beijing YouAn Hospital","startDate":"2017-04-01","conditions":"Hepatocellular Carcinoma","enrollment":10},{"nctId":"NCT05144854","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-11-05","conditions":"Gastric Cancer","enrollment":626},{"nctId":"NCT06354140","phase":"PHASE2","title":"PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-05-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT06196697","phase":"PHASE2","title":"AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-04-10","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":50},{"nctId":"NCT05498766","phase":"PHASE4","title":"Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-07-01","conditions":"Gastric Cancer","enrollment":702},{"nctId":"NCT06439550","phase":"PHASE2","title":"Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-07-15","conditions":"HER2-positive Gastric Cancer","enrollment":42},{"nctId":"NCT06396585","phase":"PHASE2","title":"The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-08-01","conditions":"Immunotherapy Gastroesophageal Junction","enrollment":28},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT06361316","phase":"NA","title":"Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Kuirong Jiang","startDate":"2024-04-08","conditions":"Pancreatic Cancer, Adjuvant Therapy","enrollment":53},{"nctId":"NCT06339619","phase":"PHASE2","title":"Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-11","conditions":"Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT06187597","phase":"PHASE2","title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":140},{"nctId":"NCT01515748","phase":"PHASE3","title":"Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12-30","conditions":"Gastric Cancer","enrollment":530},{"nctId":"NCT05960955","phase":"PHASE2","title":"Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-11-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT05914610","phase":"PHASE3","title":"Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2023-09-01","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT00004860","phase":"PHASE2","title":"Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2000-10-09","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT01845337","phase":"PHASE2","title":"Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-02-05","conditions":"Gastrointestinal Cancer, Cancer of Unknown Primary Site, Pancreatic Cancer","enrollment":59},{"nctId":"NCT05817201","phase":"PHASE2, PHASE3","title":"Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy","status":"UNKNOWN","sponsor":"Taizhou Hospital","startDate":"2022-07-01","conditions":"Esophageal Cancer, Radiation Therapy, Immunotherapy","enrollment":60},{"nctId":"NCT05774964","phase":"PHASE2","title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-15","conditions":"For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method","enrollment":100},{"nctId":"NCT05325528","phase":"PHASE2, PHASE3","title":"Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-04-10","conditions":"Liver Metastases","enrollment":40},{"nctId":"NCT05594381","phase":"PHASE2","title":"A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10","conditions":"Gastric Cancer","enrollment":90},{"nctId":"NCT05529355","phase":"PHASE2","title":"Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Anhui Chest Hospital","startDate":"2022-09-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT04856761","phase":"","title":"A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-11-01","conditions":"Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma","enrollment":160},{"nctId":"NCT03001726","phase":"","title":"To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-01","conditions":"Gastric Cancer","enrollment":228},{"nctId":"NCT03162510","phase":"PHASE1","title":"Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-06-26","conditions":"Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers","enrollment":18},{"nctId":"NCT05111444","phase":"PHASE2","title":"Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12-31","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":65},{"nctId":"NCT05070598","phase":"PHASE2","title":"Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2021-09-07","conditions":"HER2-positive Gastric Cancer","enrollment":35},{"nctId":"NCT04997837","phase":"PHASE3","title":"Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":433},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT03415802","phase":"PHASE2","title":"Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Aiping Zhou","startDate":"2015-05-11","conditions":"Advanced Pancreatic Cancer","enrollment":32},{"nctId":"NCT03154983","phase":"PHASE2","title":"The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Zhou Fuxiang","startDate":"2017-05-20","conditions":"Metastatic Gastric Cancer","enrollment":48},{"nctId":"NCT04571489","phase":"PHASE2","title":"A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-12-01","conditions":"Pancreatic Cancer","enrollment":60},{"nctId":"NCT04216758","phase":"PHASE2","title":"Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-01-01","conditions":"Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT00207831","phase":"PHASE3","title":"Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2004-07","conditions":"Rectal Cancer, Stage II/III, T3 or T4 (Only Anal Extension) Rectal Cancer","enrollment":219},{"nctId":"NCT04135781","phase":"PHASE3","title":"Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-03-01","conditions":"Stomach Cancer","enrollment":616},{"nctId":"NCT04310774","phase":"PHASE1, PHASE2","title":"CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2020-04-15","conditions":"Cervical Cancer, Chemotherapy","enrollment":200},{"nctId":"NCT03448549","phase":"PHASE3","title":"SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2018-01-01","conditions":"Colorectal Cancer Stage III, Adjuvant Chemotherapy","enrollment":1191},{"nctId":"NCT01516944","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy for Potentially Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Hebei Medical University","startDate":"2012-02","conditions":"Gastric Cancer","enrollment":749},{"nctId":"NCT03811652","phase":"PHASE1","title":"A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-12-20","conditions":"Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC)","enrollment":8},{"nctId":"NCT04202484","phase":"PHASE2","title":"Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT03941561","phase":"PHASE3","title":"S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）","status":"RECRUITING","sponsor":"Fudan University","startDate":"2019-01-01","conditions":"Gastric Cancer","enrollment":1006},{"nctId":"NCT03121313","phase":"PHASE2","title":"Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2015-02-26","conditions":"Squamous Cell Carcinoma of Oral Cavity","enrollment":68},{"nctId":"NCT03702491","phase":"PHASE2","title":"Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2018-08-10","conditions":"Gallbladder Carcinoma","enrollment":138},{"nctId":"NCT02216149","phase":"PHASE2","title":"Effects of S-1 and Capecitabine on Coronary Artery Blood Flow","status":"TERMINATED","sponsor":"Heikki Joensuu","startDate":"2015-01","conditions":"Esophagus Cancer, Stomach Cancer, Small Bowel Cancer","enrollment":20},{"nctId":"NCT03475615","phase":"PHASE3","title":"A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-03-16","conditions":"Gastric Cancer, Stomach Neoplasms","enrollment":215},{"nctId":"NCT01918852","phase":"PHASE3","title":"S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2013-12","conditions":"Colorectal Cancer, Metastases","enrollment":161},{"nctId":"NCT02359058","phase":"PHASE1","title":"A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-02","conditions":"Stomach Neoplasms","enrollment":18},{"nctId":"NCT01655992","phase":"PHASE3","title":"A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)","status":"TERMINATED","sponsor":"Fudan University","startDate":"2012-01","conditions":"Metastatic Breast Cancer","enrollment":386},{"nctId":"NCT03175705","phase":"PHASE1","title":"Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC","status":"UNKNOWN","sponsor":"Beijing YouAn Hospital","startDate":"2017-05-01","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT02527785","phase":"PHASE2","title":"Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2015-02","conditions":"Stomach Neoplasm","enrollment":44},{"nctId":"NCT03204032","phase":"PHASE2","title":"A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-10","conditions":"Extrapancreatic Neuroendocrine Tumor","enrollment":60},{"nctId":"NCT03204019","phase":"PHASE2","title":"A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-10","conditions":"Pancreatic Neuroendocrine Tumor","enrollment":60},{"nctId":"NCT03161548","phase":"PHASE2","title":"A Study of Tongue Conservation Surgery for Oral Tongue Cancer","status":"TERMINATED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2011-07-18","conditions":"Tongue Cancer, Chemotherapy Effect, Surgery","enrollment":23},{"nctId":"NCT01704690","phase":"PHASE2, PHASE3","title":"Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer","status":"TERMINATED","sponsor":"Peking University","startDate":"2012-08","conditions":"Esophageal Cancer","enrollment":4},{"nctId":"NCT02836977","phase":"NA","title":"Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-03","conditions":"Stage III Colon Cancer","enrollment":400},{"nctId":"NCT02447679","phase":"PHASE2","title":"Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2010-08","conditions":"Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Adverse Reaction to Drug","enrollment":40},{"nctId":"NCT02943252","phase":"PHASE2","title":"The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2016-10","conditions":"Head and Neck Neoplasms","enrollment":30},{"nctId":"NCT01050426","phase":"PHASE2","title":"A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2009-03","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT02903498","phase":"PHASE2","title":"The Maintenance Treatment of UFT in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-08","conditions":"Gastric Cancer","enrollment":58},{"nctId":"NCT00392899","phase":"PHASE3","title":"Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2006-10","conditions":"Colorectal Cancer","enrollment":2025},{"nctId":"NCT00898846","phase":"","title":"Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2006-10","conditions":"Colorectal Cancer","enrollment":1111},{"nctId":"NCT02887365","phase":"PHASE4","title":"A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-09","conditions":"MSI-L/MSS, Stage II Colon Cancer","enrollment":300},{"nctId":"NCT00660894","phase":"PHASE3","title":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-04","conditions":"Colorectal Cancer","enrollment":1535},{"nctId":"NCT02817425","phase":"PHASE2, PHASE3","title":"A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2013-05","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT02623153","phase":"PHASE2","title":"Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Tianshu Liu","startDate":"2016-01","conditions":"Gastric Cancer","enrollment":200},{"nctId":"NCT01539018","phase":"PHASE2","title":"Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE","status":"TERMINATED","sponsor":"Egyptian Society of Liver Cancer","startDate":"2012-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":77},{"nctId":"NCT01262274","phase":"PHASE2","title":"Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer","status":"TERMINATED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2010-12","conditions":"Breast Neoplasms","enrollment":57},{"nctId":"NCT02280070","phase":"PHASE2","title":"RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).","status":"UNKNOWN","sponsor":"Clinical Research Support Center Kyush","startDate":"2013-09","conditions":"Rectal Cancer","enrollment":110},{"nctId":"NCT00439517","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-02","conditions":"Previously Untreated Metastatic Colorectal Cancer","enrollment":302},{"nctId":"NCT01225744","phase":"PHASE2","title":"Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2009-04","conditions":"Metastatic Colorectal Cancer","enrollment":47},{"nctId":"NCT02090153","phase":"PHASE2","title":"Study of S-1 Plus LV for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-07","conditions":"Gastric Cancer","enrollment":39},{"nctId":"NCT00002801","phase":"PHASE1","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1996-04","conditions":"Colorectal Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":38,"reaction":"DIARRHOEA"},{"count":18,"reaction":"NEUTROPENIA"},{"count":14,"reaction":"ANAEMIA"},{"count":14,"reaction":"VOMITING"},{"count":11,"reaction":"DECREASED APPETITE"},{"count":11,"reaction":"DEHYDRATION"},{"count":11,"reaction":"PYREXIA"},{"count":11,"reaction":"STOMATITIS"},{"count":11,"reaction":"THROMBOCYTOPENIA"},{"count":10,"reaction":"LEUKOPENIA"}],"_approvalHistory":[],"publicationCount":466,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["UFUR","ufur","UFT"],"phase":"marketed","status":"active","brandName":"tegafur-uracil","genericName":"tegafur-uracil","companyName":"Yokohama City University","companyId":"yokohama-city-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tegafur-uracil is a chemotherapy drug combination used to treat various types of cancer, including gastric cancer, colorectal cancer, stomach neoplasm, and hepatoid adenocarcinoma of the stomach. It is a small molecule modality that works as part of a treatment regimen, often in combination with other medications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}